Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q4 2022 Earnings Presentation
17 slides from Bioporto A/s's earnings presentation, Mar 30, 2023
Slide 1: Empowering Early Detection of Kidney Injury
Empowering Early Detection of Kidney Injury 2022-Q4 Financial Results & Business Update March 30, 2023 © Copyright BioPorto | 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights from Q4 2022
Highlights from Q4 2022 • Completed submission of De Novo application to US FDA for marketing clearance of NGAL test for pediatric patients • Solid financial performance – Annual revenue of DKK 29M, a 19% increase over 2021 • Cash and cash equivalents of DKK 81.8M as of 31 Dec 2022 © Copyright BioPo
Slide 4: Acute Kidney Injury Definition
ACUTE KIDNEY INJURY Definition “AKI is a multi-dimensional, An abrupt loss of kidney function that develops rapidly over a few hours or days. multi-disciplinary problem. We really don’t understand • Symptoms may include decreased urinary output, swelling due to fluid retention, nausea, fatigue, and
Slide 5: AKI not addressed early enough can result in lifetime dialysis or death
AKI not addressed early enough can result in lifetime dialysis or death AKI – Acute Kidney Injury AKD – Acute Kidney Disease CKD – Chronic Kidney Disease © Copyright BioPorto | 5
Slide 6: AKI - an unmet clinical need for early diagnosis
AKI - an unmet clinical need for early diagnosis AKI is Common & Costly SCr is inadequate Value of Early Identification eAlert + biomarkers7 • 1 in 5 adults1 and • 2-3 days delayed response • higher rate of AKI recovery 1 in 4 children2 (+22%) • 13.3 million per year • confounded by age, muscle mass
Slide 7: NGAL testing saves lives by detecting AKI earlier
NGAL testing saves lives by detecting AKI earlier Empowers clinicians to manage fluids & nephrotoxic drugs, and determine if dialysis is needed NGAL: Neutrophil Gelatinase-Associated Lipocalin Kidney Nephron Critical care biomarker protein: • generated at all points during the waste-to- urine proces
Slide 8: Value of Early Detection
eALERT + BIOMARKERS Value of Early Detection • higher rate of kidney recovery • more dialysis-free days • shorter ICU/hospital stays • reduction in Stage 2/3 AKI • reduction in persistent AKI • earlier nephrology follow-up SOURCE: Halmy Journal of Clinical Medicine 2021 improves patient outcomes and
Slide 9: US Market: Initial FDA Clearance for Pediatric Patients
US Market: Initial FDA Clearance for Pediatric Patients We will establish a beachhead in the US market focused on testing pediatric patients - Achieved Breakthrough Status with the FDA due to the significant unmet need for pediatric patients - Pediatric market has potential for more rapid adoption o
Slide 10: C O N F I D E N T I A L | ©
C O N F I D E N T I A L | © Copyright BioPorto |
Slide 11: Kickstarting Sales Processes in Europe
Kickstarting Sales Processes in Europe • BioPorto Sales Team • Medical Affairs Team • Global Marketing • Distributor Partners Clinical Clinical Champions Workflow • CE Mark only registration required for EU Access • ~1B USD untapped market • Focus: o Select and train qualified distributor partners o
Slide 12: Acute Cardiovascular Care 2023 – Marseille France
Acute Cardiovascular Care 2023 – 24-26 March 2023 Marseille France Predictive Value of Elevated Neutrophil Gelatinase- Associated Lipocalin (NGAL) Levels for Assessment of Cardio–Renal Interactions among ST-Segment Elevation Myocardial Infarction Patients Dr. Yacov Shacham Tel Aviv University Zahler
Slide 13: BioPorto 2022 Revenue: DKKm 29.0, up 19% YTD over 2021
BioPorto 2022 Revenue: DKKm 29.0, up 19% YTD over 2021 Annual Revenue by Product Group Revenue by Quarter NGAL Tests Others 2021 Antibodies 2022 14.9 8.7 8.5 12.4 12.0 Q4 6.5 6.6 6.8 Q4 9.3 Q4 5.6 5.3 5.3 Q3 Q4 Q3 Q3 Q3 Q2 Q2 Q2 Q2 2.6 2.1 Q1 Q4 Q1 Q1 Q3 Q1 Q2 2021 2022 2021 2022 2021 2022 Q1 Q2 Q3
Slide 14: NGAL test sales up 20% YTD over 2021
NGAL test sales up 20% YTD over 2021 NGAL test sales by Quarter (LTM, DKKm) Global NGAL 20% XX% +68% NGAL 13.7 14.1 13.4 13.5 13.9 13.5 13.6 14.9 12.1 12.0 12.4 Growth in global YTD NGAL 11.3 test sales over 2021 10.5 9.4 9.5 © Copyright BioPorto | 14
Slide 15: Cash position and working capital management
Cash position and working capital management Adjusted EBITDA and cash position (DKKm) Q1 2022 Q2 2022 Q3 2022 Q4 2022 • 2022 cash burn from operations: Adj. EBITDA 107.9 DKKm 57.8, a 16% reduction vs. 2021 98.9 Cash position from favorable working capital management 81.8 • Cash balance: DKKm 81.8 27
Slide 16: 2023 Outlook
2023 Outlook Amounts in millions of Danish Kroner and US Dollars1 Actual at 2023 Outlook Dec. 31, 2022 Revenue Cash2 Adj. EBITDA loss DKK 29-33 DKK (60)-(65) DKK 82 $4.2-4.7 $(8.6)-(9.3) $11.7 1All Financial Figures Converted from DKK to USD at a rate of 6.9722:1 as of December 31, 2022. 2Audited. N
Slide 17: Investor Relations Contacts
Investor Relations Contacts CPH:BIOPOR EU: Tim Eriksen US: Ashley Robinson Managing Partner Managing Director Zenith Advisory LifeSci Advisors investor@bioporto.com arr@lifesciadvisors.com +45 4529 0000 +1 617 430 7577 © Copyright BioPorto | 17